If there is a war, INO and ONCS are ALLIES, not enemies. Electroporation ONCS uses is licensed from INO and Dhillon is on both board. INO and ONCS are brothers, and it is time for little brother tor ise.
The above flurry of positive catalysts has fueled the gain in Inovio stock, and the Roche partnership announced last month will likely add a floor to the gains, preventing the aforementioned downside correction that the stock has been subject to in the past.
The question now is, will history repeat itself and OncoSec stock price mimic that of Inovio, or has the correlation come to an end? Obviously, nobody knows for sure, but a look at OncoSec's calendar for the remainder of the year suggests there could be a similar flurry of catalysts that, if positive, might drive such correlation to continue.